Your browser is no longer supported. Please, upgrade your browser.
VYGR [NASD]
Voyager Therapeutics, Inc.
Index- P/E6.22 EPS (ttm)1.04 Insider Own0.80% Shs Outstand37.24M Perf Week-11.73%
Market Cap239.13M Forward P/E- EPS next Y-2.41 Insider Trans-9.55% Shs Float31.69M Perf Month-28.43%
Income40.10M PEG- EPS next Q-0.57 Inst Own72.40% Short Float6.02% Perf Quarter-24.77%
Sales197.30M P/S1.21 EPS this Y55.90% Inst Trans-3.47% Short Ratio3.98 Perf Half Y-45.81%
Book/sh4.46 P/B1.45 EPS next Y-386.90% ROA12.90% Target Price11.55 Perf Year-45.54%
Cash/sh5.41 P/C1.20 EPS next 5Y- ROE38.00% 52W Range6.21 - 14.62 Perf YTD-9.51%
Dividend- P/FCF- EPS past 5Y-12.10% ROI-51.90% 52W High-55.44% Beta1.03
Dividend %- Quick Ratio5.10 Sales past 5Y- Gross Margin- 52W Low4.91% ATR0.47
Employees185 Current Ratio5.10 Sales Q/Q477.50% Oper. Margin18.90% RSI (14)32.19 Volatility6.12% 6.50%
OptionableYes Debt/Eq0.00 EPS Q/Q656.40% Profit Margin20.30% Rel Volume0.67 Prev Close6.47
ShortableYes LT Debt/Eq0.00 EarningsFeb 25 AMC Payout0.00% Avg Volume478.87K Price6.51
Recom2.50 SMA20-11.77% SMA50-17.74% SMA200-38.13% Volume286,043 Change0.70%
Feb-03-21Downgrade Wedbush Outperform → Neutral $6
Feb-03-21Downgrade BTIG Research Buy → Neutral
Dec-24-20Downgrade Cantor Fitzgerald Overweight → Neutral $15 → $10
Dec-23-20Downgrade Raymond James Outperform → Mkt Perform
Nov-11-20Downgrade Oppenheimer Outperform → Perform
Nov-10-20Downgrade Wells Fargo Overweight → Equal Weight $10
Nov-10-20Downgrade Raymond James Strong Buy → Outperform $28 → $17
Mar-19-20Initiated The Benchmark Company Buy $18
Feb-06-20Initiated Oppenheimer Outperform
Nov-15-18Upgrade Raymond James Outperform → Strong Buy
Sep-10-18Resumed BTIG Research Buy $32
Sep-10-18Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-04-18Initiated H.C. Wainwright Buy $30
Mar-12-18Downgrade Wedbush Outperform → Neutral $29
Mar-12-18Downgrade Evercore ISI Outperform → In-line
Feb-02-18Initiated Morgan Stanley Overweight
Nov-28-17Resumed Piper Jaffray Overweight $28
Oct-31-17Initiated Robert W. Baird Outperform $31
Oct-27-17Initiated Canaccord Genuity Buy $35
Oct-23-17Reiterated Stifel Buy $20 → $31
Feb-24-21 02:04PM  
11:45AM  
Feb-23-21 07:45PM  
11:50AM  
11:20AM  
Feb-22-21 03:16PM  
12:30PM  
12:06PM  
Feb-20-21 05:00PM  
11:40AM  
Feb-19-21 01:00PM  
12:20AM  
Feb-18-21 11:18PM  
07:10PM  
04:01PM  
Feb-17-21 04:27PM  
10:00AM  
Feb-16-21 04:05PM  
11:04AM  
Feb-15-21 09:07PM  
03:56PM  
01:00PM  
Feb-13-21 03:50PM  
01:20PM  
01:10PM  
Feb-12-21 12:00PM  
Feb-10-21 11:40PM  
04:28PM  
11:00AM  
09:20AM  
08:00AM  
Feb-09-21 03:09PM  
11:38AM  
Feb-08-21 07:40PM  
09:51AM  
Feb-07-21 02:40PM  
Feb-06-21 11:42PM  
07:15AM  
Feb-05-21 06:13PM  
10:00AM  
Feb-04-21 12:15PM  
11:00AM  
Feb-03-21 11:10PM  
08:30PM  
02:55PM  
12:45PM  
11:00AM  
Feb-02-21 04:01PM  
12:45PM  
11:00AM  
10:25AM  
08:00AM  
Feb-01-21 12:45PM  
Jan-31-21 03:00PM  
Jan-30-21 11:45AM  
Jan-29-21 10:01PM  
04:15PM  
01:20PM  
12:46PM  
11:00AM  
Jan-28-21 11:20AM  
08:30AM  
Jan-27-21 11:55PM  
02:02PM  
12:00PM  
11:00AM  
Jan-26-21 01:23PM  
12:00PM  
10:00AM  
08:30AM  
12:06AM  
Jan-25-21 06:03PM  
02:51PM  
02:19PM  
01:49PM  
12:00PM  
11:15AM  
Jan-23-21 12:20AM  
Jan-19-21 06:26AM  
Jan-11-21 04:03PM  
09:21AM  
Dec-23-20 08:29AM  
Dec-22-20 04:17PM  
08:51AM  
Dec-09-20 09:43PM  
04:02PM  
Nov-16-20 09:48AM  
Nov-09-20 05:15PM  
04:00PM  
Oct-28-20 12:32PM  
Oct-21-20 08:27PM  
Oct-13-20 09:10AM  
03:24AM  
Oct-12-20 04:01PM  
Oct-01-20 04:01PM  
Sep-15-20 04:01PM  
Sep-14-20 04:30PM  
Sep-11-20 03:27PM  
12:25PM  
11:36AM  
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia; and alpha-synuclein program for synucleinopathies, Parkinson's disease, Lewy Body Dementia, and multiple system atrophy. The company has strategic collaboration agreements with the University of Massachusetts; and ClearPoint Neuro, Inc., as well as collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Turenne AndrePresident & CEOFeb 11Sale7.557,97760,226148,375Feb 16 04:11 PM
Dorval AllisonChief Financial OfficerFeb 11Sale7.553,18624,05445,894Feb 16 04:10 PM
Hesslein Robert W.Senior VP & General CounselFeb 11Sale7.553,18624,05449,348Feb 16 04:08 PM
Khwaja OmarSee remarksFeb 11Sale7.553,47526,23653,025Feb 16 04:06 PM
Turenne AndrePresident & CEOJan 12Sale8.6210,44390,019156,352Jan 14 05:59 PM
Dorval AllisonChief Financial OfficerJan 12Sale8.622,94225,36049,080Jan 14 05:57 PM
Khwaja OmarSee remarksMay 21Sale12.963,50045,36056,500May 22 06:15 PM
Hesslein Robert W.Senior VP & General CounselApr 03Sale8.513,09126,30452,534Apr 07 05:24 PM